Source:http://linkedlifedata.com/resource/pubmed/id/18656539
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2008-12-10
|
pubmed:abstractText |
5-Fluorouracil (5-FU) is an antimetabolite with a broad-spectrum activity against solid tumors. However, its very short half-life in plasma circulation greatly limited the in vivo antitumor efficacy and clinical application. The current work aimed to solve this problem as well as to increase 5-FU biodistribution to tumor by covalently conjugating 5-FU to a biocompatible, non-toxic and non-immunogenic drug carrier -N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer. The in vitro cytotoxicity, in vivo biodistribution and therapeutic efficacy of HPMA copolymer-5-FU conjugates (P-FU) were reported. Cytotoxicity was evaluated by using a serial of tumor cells (A549, CT-26, Hela, HepG(2) cells and 5-FU resistant HepG(2) cells). In vivo biodistribution and therapeutic efficacy were investigated in Kunming mice-bearing hepatoma 22 (H(22)). Results indicated that P-FU could increase the cytotoxicity of 5-FU in Hela, HepG(2) and 5-FU resistant HepG(2) cells, while it decreases the cytotoxicity of 5-FU in A549 and CT-26. Both in vitro release profile in plasma and biodistribution study showed that P-FU significantly prolonged the drug plasma circulation time. P-FU also showed an over 3-fold larger area under the concentration-time curve (AUC) in tumor when compared with free drug. Therapeutic evaluation also demonstrated that the treatment with P-FU displayed stronger inhibition of the tumor growth when compared with that of control group (physiologic saline) or 5-FU group at the same dose. All the results suggested that P-FU could increase cytotoxicity of 5-FU in certain cancer cell lines, prolong 5-FU circulation time in vivo, enhance 5-FU distribution to tumor and improve therapeutic efficacy. Therefore, HPMA copolymer is a potential carrier for 5-FU for the effective treatment of cancer.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Acrylamides,
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Carriers,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/N-(2-hydroxypropyl)methacrylamide
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0939-6411
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
70
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
770-6
|
pubmed:meshHeading |
pubmed-meshheading:18656539-Acrylamides,
pubmed-meshheading:18656539-Animals,
pubmed-meshheading:18656539-Antimetabolites, Antineoplastic,
pubmed-meshheading:18656539-Biological Availability,
pubmed-meshheading:18656539-Cell Survival,
pubmed-meshheading:18656539-Chemistry, Pharmaceutical,
pubmed-meshheading:18656539-Drug Carriers,
pubmed-meshheading:18656539-Drug Compounding,
pubmed-meshheading:18656539-Drug Stability,
pubmed-meshheading:18656539-Female,
pubmed-meshheading:18656539-Fluorouracil,
pubmed-meshheading:18656539-HeLa Cells,
pubmed-meshheading:18656539-Humans,
pubmed-meshheading:18656539-Inhibitory Concentration 50,
pubmed-meshheading:18656539-Liver Neoplasms, Experimental,
pubmed-meshheading:18656539-Mice,
pubmed-meshheading:18656539-Time Factors
|
pubmed:year |
2008
|
pubmed:articleTitle |
In vitro cytotoxicity, in vivo biodistribution and antitumor activity of HPMA copolymer-5-fluorouracil conjugates.
|
pubmed:affiliation |
Key Laboratory of Drug Targeting and Drug Delivery, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, PR China.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|